Please login to the form below

Not currently logged in
Email:
Password:

Roche's anti-obesity drug Xenical faces generic competition in UK

Teva launches first generic version of orlistat

Roche's anti-obesity brand Xenical (orlistat) is facing generic competition in the UK after Teva launched its version of the drug.

The company will sell its prescription-only version of Xenical at £27.60 for 120mg capsule x 84, under-cutting the £31.63 list price of Roche's branded version.

Kim Innes, commercial director at Teva, said: "We're delighted to be the first company to launch generic orlistat in the UK.

"As the UK's leading supplier of generics, we're pleased not only to have the widest portfolio of our competitors, but also to show that we're well-placed when it comes to innovation and being the first to market."

Xenical is indicated to treat obese patients with a body mass index (BMI) greater or equal to 30kg/m2, or overweight patients (BMI greater than or equal to 28kg/m2) with associated risk factors, in conjunction with a mildly hypocaloric diet.

The drug is also marketed in a reduced strength, non-prescription form by GlaxoSmithKline (GSK) as Alli, but the company is planning to divest it and other non-key OTC brands.

12th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics